中金发表研报指，药明合联(02268.HK) 2024年业绩符合预期，收入按年增长90.8%，净利润增长277.2%，毛利率按年提升4.2个百分点至30.6%，净利率亦提升13个百分点至26.4%，利润能力迅速提升，考虑到订单增长趋势依然强劲，将2025年和2026年经调整净利润预测上调7.4%和12.2%，目标价上调至45元，维持“跑赢行业”评级。(gc/a)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-27 12:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.